Product Reports Resources Pricing Login Book a demo
Alexis Borisy
Person deep dive

Alexis Borisy

Alexis Borisy is a Boston biotech founder who co-founded Foundation Medicine, which Roche bought out in 2018 at a $5.3B value, and Blueprint Medicines, which Sanofi bought for up to $9.5B in 2025. He now runs Curie.Bio and chairs Relay Therapeutics.

Founded
Curie.Bio, IDRx, EQRx +5 more
Education
The University of Chicago, Harvard University

Track record

Companies Alexis Borisy founded or backed, with what became of them.

Curie.Bio

FirmCurie.Bio
Founded2022
FocusSeed funding and company-building support for biotech founders

Career

  1. 2000Founds CombinatoRx and runs it as CEO, later taking it public on Nasdaq.
  2. 2010Joins Third Rock Ventures as a partner and co-founds Foundation Medicine.
  3. 2011Co-founds Blueprint Medicines and joins its board.
  4. 2018Roche buys the rest of Foundation Medicine for $2.4B, valuing it at $5.3B.
  5. 2019Leaves Third Rock and founds EQRx to make lower-priced drugs.
  6. 2022Co-founds IDRx and Curie.Bio.
  7. 2023Revolution Medicines buys EQRx and winds down its drug programmes.
  8. 2025GSK buys IDRx for up to $1.15B. Sanofi buys Blueprint Medicines for up to $9.5B.

Sources: Alexis Borisy, Relay Therapeutics · Alexis Borisy, Blueprint Medicines · Roche buys Foundation Medicine for $2.4B (Medical Xpress, 2018) · Revolution Medicines completes acquisition of EQRx · GSK completes $1.15B acquisition of IDRx (DCAT) · Alexis Borisy, Dealroom.

Companies founded

Currently

Active roles, board seats and partnerships.

Work history

Past roles by Dealroom records.

Education

The University of Chicago
Bachelor · Chemistry · 1980 – 1993
Harvard University
Masters · Chemical Biology, Chemistry · until 1995
← All people